Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 7, 2022; 10(1): 12-22
Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.12
Hepatitis B virus reactivation in rheumatoid arthritis
Ya-Li Wu, Jing Ke, Bao-Yu Zhang, Dong Zhao
Ya-Li Wu, Jing Ke, Bao-Yu Zhang, Dong Zhao, Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China
Author contributions: Wu YL drafted the article; Ke J, Zhang BY, and Zhao D critically revised and prepared the manuscript; all authors read and approved the submitted version of the manuscript.
Conflict-of-interest statement: The authors declare that they have no actual or potential competing interest related to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dong Zhao, MD, PhD, Associate Professor, Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, No. 82 Xinhua South Road, Tongzhou District, Beijing 101149, China. zhaodong@ccmu.edu.cn
Received: June 7, 2021
Peer-review started: June 7, 2021
First decision: September 1, 2021
Revised: September 16, 2021
Accepted: November 28, 2021
Article in press: November 28, 2021
Published online: January 7, 2022
Core Tip

Core Tip: The application of anti-viral drugs and anti-rheumatic drugs improves the prognosis of patients with hepatitis B virus (HBV) infection and rheumatoid arthritis (RA). However, the reactivation of HBV in RA patients has not attracted enough attention. Although the HBV infection rate in RA patients is not high, once HBV reactivation (HBVr) occurs, it will cause serious consequences. Therefore, patients with HBV infection should undergo comprehensive evaluation before anti-rheumatic drug treatment. This paper summarizes the mechanism of HBVr, the risk of HBVr caused by anti-rheumatic drugs, and the appropriate diagnosis and treatment process for RA patients.